Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/19/2026, 12:00:00 AM
The U.S. FDA approved Wegovy® HD (semaglutide 7.2 mg), a higher dose for weight management, which showed a mean weight loss of 20.7% in trials. Analysts estimate this approval will drive significant revenue growth, and the U.S. launch is expected in April 2026.
Korean Translation
미국 FDA는 체중 관리를 위한 고용량 버전인 위고비® HD(세마글루타이드 7.2mg)를 승인했으며, 임상시험에서 평균 20.7%의 체중 감소를 보임. 애널리스트들은 이 승인이 매출 성장을 견인할 것으로 예상하며, 2026년 4월 미국 출시가 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
First quarter 2026 earnings release and conference call scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
First quarter 2026 financial results and conference call scheduled for 2026-04-30. Routine earnings announcements typically result in minor price fluctuations (Low importance) scheduled.
4/30/2026, 12:00:00 AM
Medpace Holdings Inc (MEDP) · Earnings Release
First quarter 2026 financial results to be reported after market close on April 22, 2026. Importance is estimated as High as earnings releases typically cause significant price volatility, scheduled.
4/22/2026, 12:00:00 AM